Ali Fatemi

Ali Fatemi, MD, MBA, serves as Chief Medical Officer at Kennedy Krieger Institute and Professor of Neurology and Pediatrics at Johns Hopkins University School of Medicine. He directs the Division of Neurogenetics and the Moser Center for Leukodystrophies, holding the Blum-Moser Chair for Pediatric Neurology while leading research at the Hugo W. Moser Research Institute.

• Medical degree, Medical University of Vienna (1999)
• Post-doctoral fellowship in neurogenetics, Kennedy Krieger Institute (2001)
• Child neurology residency, Massachusetts General Hospital/Harvard Medical School

Dr. Fatemi's research integrates bench and clinical investigations focused on white matter disorders. His laboratory pioneers oligodendroglial biology, cell-based therapies using glial restricted precursors, and nanomedicine applications for myelination disorders. Clinically, he specializes in X-linked adrenoleukodystrophy and genetic causes of cerebral palsy, with work demonstrating that genomic diagnosis significantly impacts management of neurodevelopmental disabilities.

Analysis of his publication record reveals sustained focus on leukodystrophy mechanisms and therapeutic innovation, leveraging advanced neuroimaging (diffusion tensor, magnetization transfer MRI) and regenerative approaches. His interdisciplinary work bridges neurology, genetics, and nanotechnology to address rare white matter diseases.

Dr. Fatemi's 2014 study in Annals of Neurology was recognized by Neurology Today as one of the year's top neurogenetics findings. He serves on the Scientific Advisory Board of the United Leukodystrophy Foundation and Drug Safety Monitoring Boards for clinical trials.

As an active mentor and grant-funded investigator, he oversees translational research programs while serving on journal review panels. His leadership in the Moser Center drives collaborative efforts in leukodystrophy diagnosis and treatment development.

Dr. Fatemi directs the Moser Center for Leukodystrophies research team, which includes nanomedicine specialists and neuroimaging experts developing therapies for white matter injury. His laboratory's work on glial restricted precursors and nanodendrimers represents cutting-edge approaches to myelin repair.